Agios Pharmaceuticals
AGIO
27.60
-1.16
-4.03%
Agios Pharmaceuticals
US · AGIO
#2841 by market cap
Listed 1970
27.60
-1.16
-4.03%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership rose 5.0 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 117.18% +4.99pp
- Institutions
- 295 +10
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund67.72%
Hedge Fund34.00%
Public Company8.36%
Private Company4.41%
VC/PE Fund1.31%
Individual/Insider1.11%
Insurance Company0.93%
Government Pension Fund0.43%
Top holders as of 2026-09-30
BlackRock
10.42% · 6.23M sh
Farallon Capital Management, L.L.C.
9.89% · 5.92M sh
Morgan Stanley
5.75% · 3.44M sh
Lynx1 Capital Management LP
5.70% · 3.41M sh
State Street Global Advisors
5.46% · 3.26M sh
D. E. Shaw & Co., L.P.
5.19% · 3.11M sh
Vanguard Portfolio Management, LLC
4.77% · 2.85M sh
Vanguard Capital Management, LLC
4.49% · 2.69M sh
Armistice Capital LLC
4.01% · 2.40M sh
Erste Asset Management GmbH
3.61% · 2.15M sh
Macquarie Investment Management Business Trust
3.53% · 2.11M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 13 sells
| Name | Role | Stake |
|---|---|---|
| Brian Goff | Chief Executive Officer | 0.31% |
| Jacqualyn Fouse | Chair of the Board of Directors | 0.26% |
| Cecilia Jones | Chief Financial Officer | 0.09% |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 0.09% |
| James Burns | Chief Legal Officer | 0.08% |
| Tsveta Milanova | Chief Commercial Officer | 0.08% |
| David Scadden | Independent Director | 0.03% |
| Maykin Ho | Independent Director | 0.03% |
| Cynthia Smith | Independent Director | 0.03% |
| Rahul Ballal | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-25 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -7,866 | $37.69 |
| 2026-10-25 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -7,866 | $25.01–37.69 |
| 2026-10-21 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -1,989 | $25.01–37.53 |
| 2026-10-21 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -500 | $37.52 |
| 2026-10-20 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -1,489 | $37.53 |
| 2026-08-03 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -30,000 | $30.48 |
| 2026-07-07 | Jay Backstrom | Independent Director | Other Acquisition | +1,447 | -- |
| 2026-06-30 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -4,007 | $37.56 |
| 2026-06-30 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Retained | +4,368 | -- |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Jeffrey Capello | Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Jay Backstrom | Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jay Backstrom | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Agios Pharmaceuticals discussion 0 comments